Bangladesh is a South Asian country with very limited resources for providing health service to its 1.8 Million population in a sustainable manner. Under the global COVID pandemic, there is a national pressure to divert funds to the rescue of the citizens directly affected by the disease, and those indirectly affected by the economic slowdown. In both cases, with its limited financial resources, Bangladesh is unable to support its people, and is possibly set towards a non-recoverable crisis. A rapid shutdown to the coronavirus spread is needed in the country and this project will leverage the available stringent resources to build a viable solution.
It is proposed that a plasma bank will be established in Bangladesh, which will be a platform for collection of information in a database from individuals who have fully recovered from COVID-19. Convalescent plasma is the liquid part of blood that is collected from patients who have recovered from the novel coronavirus disease, COVID-19, caused by the virus SARS-CoV-2. As a defense mechanism of the body, COVID-19 patients develop antibodies in the blood against the virus, which are proteins that might help fight the infection. Convalescent plasma is being investigated for the treatment of COVID-19 because there is no approved treatment for this disease and there is information that suggests it might help some patients recover from COVID-19.
There is a possibility that people who have fully recovered from COVID-19 in Bangladesh, may be able to help patients currently fighting the infection by donating their plasma. Because they fought the infection, their plasma now contains COVID-19 antibodies. These antibodies provided one way for their immune system to fight the virus when they were sick, so this plasma may be able to be used to help others fight off the disease.
In order to help deployment, the proposed solution for the prevention and treatment of COVID-19, a testing program will be introduced through the proposed Plasma bank database. This COVID-19 testing facility will be established based upon the guidelines of the World Health Organization (WHO). A virtual digital platform will keep record of test results with identification of all individuals being tested. As a part of the treatment procedure, COVID-19 affected patients will be given access to this information and guidance for collecting convalescent plasma from the donor. A close monitoring of recovery of the patient through plasma transfusion will be followed up for a year.
Among other factors, regulatory and logistical requirements of plasma collection process will need guidelines and authorization of GOB. Global standards (established through clinical trials) will be followed for defining criteria for donor eligibility, donor recruitment, collections and transfusion of plasma itself.